| 吉非替尼治疗晚期非小细胞肺癌的临床分析 |
| |
| 引用本文： | 徐美玲,林媛媛,曲文洁.吉非替尼治疗晚期非小细胞肺癌的临床分析[J].山东医学高等专科学校学报,2012,34(5):365-367. |
| |
| 作者姓名： | 徐美玲 林媛媛 曲文洁 |
| |
| 作者单位： | 平度市人民医院,山东平度,266700 |
| |
| 摘 要： | 目的 观察吉非替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效及安全性.方法 回顾性分析30例接受吉非替尼治疗的NSCLC患者的临床资料,评估其临床疗效及不良反应的发生情况.结果 30例入组患者中,1例达到CR,8例PR,12例SD,9例PD,有效率为30％(9/30),疾病控制率70％(21/30);皮疹发生率为43.3％(13/30),腹泻发生率为16.7％(5/30),均为Ⅰ～Ⅱ.结论 吉非替尼治疗晚期NSCLC有较好的疗效,安全性高.
|
| 关 键 词： | 非小细胞肺癌 吉非替尼 靶向治疗 |
CLINICAL EFFECT OF GEFITINIB ON ADVANCED NON-SMALL CELL LUNG CANCER |
| |
| XU Mei-Ling
,
LIN Yuan-yuan
,
QU Wen-jie.CLINICAL EFFECT OF GEFITINIB ON ADVANCED NON-SMALL CELL LUNG CANCER[J].Journal of Shandong Medical College,2012,34(5):365-367. |
| |
| Authors: | XU Mei-Ling LIN Yuan-yuan QU Wen-jie |
| |
| Institution: | (Pingdu City People’s Hospital,Pingdu,China 266700) |
| |
| Abstract: | Objective To observe the therapeutic effect and safety of Gefitinib in treating advanced non-small cell lung cancer(NSCLC).MethodsThe clinical data of 30 cases of NSCLC were retrospectively analyzed The therapeutic effects and adverse reactions were evaluated.ResultsAmong the 30 patients,one patient got complete remission(CR) and 8 got partial remission(PR),12 had their disease stabilized and 9 got progression.The effective rate was 30% and the disease control rate was 70%.The incidence of rash was 43.3%,and the incidence of diarrhea was 16.7%,both at Stage I-II.ConclusionGefitinib can produce good effects on advanced NSCLC. |
| |
| Keywords: | Non-small cell lung cancer Gefitnib Targeted therapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
